Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

418 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Platinum-based adjuvant chemotherapy on moderate- and high-risk stage I and II epithelian ovarian cancer patients. Long-term single institution experience and literature review.
García-Sáenz JA, Custodio A, Casado A, Vidart JA, Coronado PJ, Martín M, López-Tarruella S, Puente J, Fernández C, Díaz-Rubio E. García-Sáenz JA, et al. Among authors: puente j. Clin Transl Oncol. 2011 Feb;13(2):121-32. doi: 10.1007/s12094-011-0629-6. Clin Transl Oncol. 2011. PMID: 21324801 Review.
Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study.
Garcia-Donas J, Esteban E, Leandro-García LJ, Castellano DE, González del Alba A, Climent MA, Arranz JA, Gallardo E, Puente J, Bellmunt J, Mellado B, Martínez E, Moreno F, Font A, Robledo M, Rodríguez-Antona C. Garcia-Donas J, et al. Among authors: puente j. Lancet Oncol. 2011 Nov;12(12):1143-50. doi: 10.1016/S1470-2045(11)70266-2. Epub 2011 Oct 17. Lancet Oncol. 2011. PMID: 22015057
Sequential therapy in metastatic renal cell carcinoma: pre-clinical and clinical rationale for selecting a second- or subsequent-line therapy with a different mechanism of action.
González Larriba JL, Espinosa E, García Carbonero I, García-Donas J, López M, Meana A, Puente J, Bellmunt J. González Larriba JL, et al. Among authors: puente j. Cancer Metastasis Rev. 2012 Sep;31 Suppl 1:S11-7. doi: 10.1007/s10555-012-9354-z. Cancer Metastasis Rev. 2012. PMID: 22674353 Review.
Prospective study assessing hypoxia-related proteins as markers for the outcome of treatment with sunitinib in advanced clear-cell renal cell carcinoma.
Garcia-Donas J, Leandro-García LJ, González Del Alba A, Morente M, Alemany I, Esteban E, Arranz JA, Climent MA, Gallardo E, Castellano DE, Bellmunt J, Mellado B, Puente J, Moreno F, Font A, Hernando S, Robledo M, Rodríguez-Antona C. Garcia-Donas J, et al. Among authors: puente j. Ann Oncol. 2013 Sep;24(9):2409-14. doi: 10.1093/annonc/mdt219. Epub 2013 Jun 20. Ann Oncol. 2013. PMID: 23788753 Free article.
Identification of tissue microRNAs predictive of sunitinib activity in patients with metastatic renal cell carcinoma.
Prior C, Perez-Gracia JL, Garcia-Donas J, Rodriguez-Antona C, Guruceaga E, Esteban E, Suarez C, Castellano D, del Alba AG, Lozano MD, Carles J, Climent MA, Arranz JA, Gallardo E, Puente J, Bellmunt J, Gurpide A, Lopez-Picazo JM, Hernandez AG, Mellado B, Martínez E, Moreno F, Font A, Calvo A. Prior C, et al. Among authors: puente j. PLoS One. 2014 Jan 24;9(1):e86263. doi: 10.1371/journal.pone.0086263. eCollection 2014. PLoS One. 2014. PMID: 24475095 Free PMC article.
Recommendations from the Spanish Oncology Genitourinary Group for the treatment of patients with renal cell carcinoma.
García Del Muro X, Gallardo E, García Carbonero I, Laínez N, José Méndez M, Maroto P, Ochoa de Olza M, Puente J, Reynes G, Rubio J, Santander C, Suárez C, Vázquez Estévez S, Castellano D. García Del Muro X, et al. Among authors: puente j. Cancer Chemother Pharmacol. 2014 Jun;73(6):1095-107. doi: 10.1007/s00280-014-2413-0. Epub 2014 Feb 16. Cancer Chemother Pharmacol. 2014. PMID: 24531612 Review.
SEOM clinical guidelines for the treatment of renal cell carcinoma.
Bellmunt J, Puente J, Garcia de Muro J, Lainez N, Rodríguez C, Duran I; Spanish Society for Medical Oncology. Bellmunt J, et al. Among authors: puente j. Clin Transl Oncol. 2014 Dec;16(12):1043-50. doi: 10.1007/s12094-014-1219-1. Epub 2014 Oct 2. Clin Transl Oncol. 2014. PMID: 25274276 Free PMC article.
418 results